Most of Bayer’s prescription dermatology brands to be sold off

LEO Pharma is set to buy the global product rights of Bayer’s prescription dermatology business (excluding Pakistan and Afghanistan, and Bayer’s OTC dermatology portfolio). It with acquire the branded topical prescription treatments Travogen and Travocort for fungal skin infections, Skinoren for acne and Finacea for rosacea, together with a selection of topical steroids such as Nerisona, Advantan and Desonate which had an annual turnover of over €280m last year, and is expected to double sales in some markets.
Gitte Aabo, LEO Pharma president and CEO, said: “With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We will broaden our treatment range and considerably enhance our size in key markets around the world – underlining our ambition to be a preferred partner in medical dermatology.”